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Abstract
Background: Diabetes is among the strongest predictors of outcome after coronary artery stenting and the
incidence of negative outcomes is still high in this specific group. Data of long-term outcomes comparing diabetic
patients with non-diabetic patients treated with bioresorbable scaffolds are still incomplete. This work evaluates the
long-term outcomes after implantation of a coronary bioresorbable scaffold (BRS) in diabetic patients compared to
non-diabetics.
Methods: Patients who received at least one Absorb BRS in the time of May 2012 to December 2014 were enrolled
into this single-center registry. Quantitative coronary angiography (QCA) was performed.
Results: Six hundred fifty seven patients including 138 patients (21%, mean age 65 ± 11, 78% male) with diabetes
were enrolled.
Patients in the diabetic group were significantly older, were more likely to suffer from hypertension and
hyperlipidemia and had more often a prior stroke or TIA as well as a reduced renal function (all P < 0.05). The initial
stenosis was less severe in the diabetic group (74.8% vs. 79.6%, P = 0.036), but the residual stenosis after BRS
implantation exceeded that of the control group (16.7% vs. 13.8%, P = 0.006).
History of diabetes had no impact on the incidence of events within one year after BRS implantation. Beyond
1 year, diabetic patients had a higher incidence of cardiovascular death (6.9 vs. 1.4%, HR:5.37 [1.33–21.71], P = 0.001),
scaffold restenosis (17.6 vs. 7.8%, HR:3.56 [1.40–9.05], P < 0.0001) and target lesion revascularization (P = 0.016). These
results were confirmed in the propensity score analysis.
In both diabetics and non-diabetics, there was a strong association (HR:18.6 [4.7–73.3]) between the risk of
restenosis and the technique used at implantation; in contrast, the impact of vessel size was more manifest in non-
diabetics than in diabetic patients, and an increased risk of restenosis was demonstrated for both large and small
vessels.
Conclusion: As for metal stents, beyond one year after implantation, diabetes was associated with an increased
incidence of scaffold restenosis and related outcomes. This negative impact of diabetes was reset when an optimal
implantation technique was used.
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Background
Due to the higher prevalence of complex clinical and
angiographic features, diabetes is among the strongest
predictors of outcome after coronary artery stenting [1].
While being associated with a significant improvement
as compared to bare metal stents, the rate of target-
lesion failures following use of modern drug eluting
stents in diabetics still remains as high as 2–4% per year,
and diabetes remains an important factor in the decision
regarding the revascularization strategy to be followed,
particularly in patients with multivessel disease [2, 3].
Bioresorbable coronary scaffolds (BRS) were developed
to reduce late-occurring complications of stenting and
were brought to the EU market in 2012 without restric-
tion for the type of (de novo) lesion or the clinical set-
ting in which they were to be used [4]. Particularly in
the setting of diabetes, where the chronic inflammatory
environment is felt to be associated with stent failure
[5], the resorption of the scaffold strut might theoretic-
ally provide an advantage over permanent metallic de-
vices. Recent data [6–8], however, point out at increased
rates of target lesion failure in patients treated with BRS
as compared to those treated with newer generation
drug eluting stents, an observation which lead first to
the restriction of BRS to registries and then to the re-
moval of Absorb BRSs from the market. While evidence
regarding the role of procedural parameters has been
well investigated [9, 10], less evidence is available regard-
ing clinical features as predictors of risk after BRS im-
plantation. In particular, diabetes has been shown to be
a predictor of target lesion failure in registry studies with
a 6-months to 1-year follow-up [11–13], but not in a
pooled analysis of the ABSORB cohort B, ABSORB Ex-
tend and SPIRIT trials [14]. In a smaller study with a 3-
years follow-up [15], numerically more target lesion fail-
ures were reported, but the difference against non-
diabetic patients was not significant. Other than this
study, data on long-term outcomes are missing. Such
data are particularly important because the risk of re-
stenosis, and therefore the impact of diabetes, would be
expected to increase later than one year after implant-
ation. In the present paper, we report on the 3- to 4-
years outcomes of patients with diabetes treated with
Absorb BRS in a larger cohort of consecutive patients.
Methods
Study design
This investigator-initiated, single-centre, single-arm ob-
servational study enrolled consecutive patients who re-
ceived one or more Absorb BRS (Abbott Vascular, Santa
Clara, CA, USA) at the University hospital of Mainz be-
tween May 2012 and December 2014. The outcome after
BRS implantation in patients with diabetes mellitus was
compared to that of non-diabetes patients.
Follow-up data were obtained in the setting of office
visits or telephone calls and entered retrospectively in
the research database. Trained medical staff obtained
data using a standardized questionnaire. In the case of
hospital admission or events, original medical docu-
ments were obtained from the patients, treating cardiol-
ogists or general practitioners. Events were adjudicated
by consensus of at least two experienced interventional-
ists. The study belongs to the MICAT project
(NCT02180178), which is approved by the local ethics
committee.
BRS implantation
As published before [16], BRS were not used for sten-
oses in the left main coronary or vein grafts, in-stent re-
stenosis, bifurcation lesions with side branches > 2 mm.
Furthermore, patients with intolerance to aspirin or thie-
nopyridines, pre-existing therapy with anticoagulants or
patients with limited life expectancy received no BRS.
Predilatation was systematically used; postdilatation was
systematically used starting from January 2014. Dual an-
tiplatelet therapy for 12 months (aspirin plus clopidogrel
for stable disease; aspirin plus prasugrel/ticagrelor for
acute coronary syndromes) was recommended.
Quantitative coronary analysis
Quantitative coronary analysis (QCA) was performed
off-line by trained personnel blinded to the patients´
clinical characteristics and outcomes. Parameters in-
cluded lesion length, interpolated reference vessel diam-
eter (RVD) and minimum lumen diameter (MLD) before
and after implantation. Initial stenosis, residual stenosis
and lumen gain was calculated by these parameters:
Initial=residual stenosis ¼ 1–MLD=RVD
Lumen gain ¼MLD postprocedural–MLD preprocedural
Xcelera R 4.1 (Philips, the Netherlands) was used for
these measurements; detailed methods, reproducibility
and repeatability data have already been published be-
fore [17].
Endpoints
Events were defined according to the academic research
consortium definitions [18]. Events were analysed separ-
ately for early (< 30 days), late (31–365 days), very late
(> 365 days) timepoints and as overall occurrence. End-
points included death, cardiovascular death (CV death),
myocardial infarction (MI) and target vessel MI (TVMI),
target lesion revascularization (TLR), target vessel revas-
cularization (TVR), clinically relevant scaffold restenosis
(ScR) and scaffold thrombosis (ScT). TLR was defined as
any revascularization of the original segment (scaffold +
5 mm proximal and distal). CV death, TVMI and TLR
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Table 1 Patient and procedural characteristics
All patients (n = 657) Patients with diabetes (n = 138) Patients without diabetes (n = 519) P-value
Age (years) 63 ± 12 65 ± 11 62 ± 12 0.015
Male 519/657 (79.0%) 107/138 (77.5%) 412/519 (79.4%) 0.722
Hypertension 478/657 (72.8%) 117/138 (84.8%) 361/519 (69.6%) < 0.001
Smoking 273/657 (41.6%) 48/138 (34.8%) 225/519 (43.3%) 0.086
Family History 138/657 (21.0%) 21/138 (15.2%) 117/519 (22.5%) 0.078
Hyperlipidemia 268/657 (40.8%) 76/138 (55.1%) 192/519 (37.0%) < 0.001
Prior CABG 14/657 (2.1%) 5/138 (3.6%) 9/519 (1.7%) 0.186
Prior PCI 181/657 (27.5%) 48/138 (34.8%) 133/519 (25.6%) 0.042
Prior stroke/TIA 27/657 (4.1%) 11/138 (8.0%) 16/519 (3.1%) 0.020
eGFR (ml/min) 83 ± 23 76 ± 25 84 ± 22 < 0.001
LVEF (%) 52 ± 8 53 ± 7 52 ± 9 0.590
Silent/stable angina 219/657 (33.3%) 56/138 (40.6%) 163/519 (31.4%) 0.054
Unstable Angina 78/657 (11.9%) 20/138 (14.5%) 58/519 (11.1%) 0.356
NSTEMI 191/657 (29.1%) 33/138 (23.9%) 158/519 (30.4%) 0.163
STEMI 166/657 (25.3%) 28/138 (20.3%) 138/519 (26.6%) 0.161
Lesion characteristics
LAD treated with BRS 301/657 (45.8%) 68/138 (49.3%) 233/519 (44.9%) 0.411
LCX treated with BRS 161/657 (24.4%) 36/138(26.1%) 125/519(24.1%) 0.708
RCA treated with BRS 194/657 (29.7%) 34/138 (24.6%) 160/519 (30.8%) 0.190
Graft treated with BRS 1/657 (0.2%) 0/138 (0%) 1/519 (0.2%) 1
Ostial lesion 53/657 (8.1%) 10/138 (7.2%) 43/519 (8.3%) 0.824
CTO 11/657(1.7%) 2/138 (1.4%) 15/519 (2.9%) 0.546
Bifurcation 82/657(12.5%) 13/138(9.4%) 69/519(13.3%) 0.281
At least one lesion type B2 or C 297/657 (45.2%) 62/138 (44.9%) 235/519 (45.3%) 0.982
Procedural characteristics
Number of vessels treated with BVS 1.2 ± 0.4 1.2 ± 0.5 1.1 ± 0.4 0.095
Number of BRS per patient 1.4 ± 0.8 1.5 ± 0.9 1.4 ± 0.8 0.181
vHybrid BRS + DES 330/657(50.2%) 56/138(40.6%) 274/519(52.8%) 0.014
Predilatation 653/657(99.4%) 136/138(98.6%) 517/519(99.6%) 0.196
Diameter predilatation ballon (mm) 2.80 ± 0.37 2.83 ± 0.36 2.80 ± 0.37 0.367
Minimum stent diameter per patient (mm) 2.97 ± 0.38 2.96 ± 0.36 2.98 ± 0.38 0.572
Total implanted length per patient (mm) 27.5 ± 18.9 29.0 ± 19.4 27.2 ± 18.8 0.324
Postdilatation 306/657(46.6%) 71/138(51.4%) 235/519(45.3%) 0.232
Preprocedural RVD, mm 2.93 ± 0.67 2.91 ± 0.77 2.94 ± 0.65 0.728
Preprocedural MLD, mm 0.61 ± 0.51 0.71 ± 0.41 0.58 ± 0.54 0.026
% stenosis per lesion 78.2 ± 17.9 74.6 ± 13.6 79.4 ± 18.8 0.014
Angiographic Outcome
Postprocedural RVD, mm 3.0 ± 0.5 3.0 ± 0.4 3.0 ± 0.5 0.760
vPostprocedural MLD, mm 2.5 ± 0.5 2.5 ± 0.5 2.5 ± 0.5 0.135
Residual stenosis per lesion (%) 14.5 ± 10.8 16.7 ± 13.2 13.7 ± 9.9 0.018
MLD/nominal BRS diameter 0.84 ± 0.13 0.82 ± 0.16 0.85 ± 0.13 0.101
Lumen Gain, mm 1.63 ± 0.62 1.61 ± 0.61 1.68 ± 0.56 0.382
Optimal implantation technique 311/657 (47.3%) 74/138 (53.6%) 237/519 (45.7%) 0.117
Overlap 74/657 (11.3%) 12/138 (8.7%) 62/519 (11.9%) 0.357
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were analyzed together as device-oriented composite
endpoint (DoCE).
Statistical methods
Continuous data were presented as mean and stand-
ard deviation (SD) or median (interquartile range)
and are analysed with parametric or non-parametric
tests as appropriate; categorical data are presented as
total numbers and proportions and were analysed
with Chi square or Fisher’s exact test. Analysis of the
outcome of diabetes patients compared to non-
diabetes patients treated with BRS was performed
with cox regression analysis and is illustrated in
Kaplan-Meier curves. All variables listed in Table 1
were tested at univariate level and those with a P < 0.
1 were introduced in a multivariable model. To re-
move potential bias, propensity score analysis was
performed for DoCE, ScR and ScT using the inverse
probability treatment weighted analysis method and
average treatment effect adjustment. This method
uses propensity score-based weights to create a sam-
ple in which the distribution of covariates is inde-
pendent of the group. Parameters for the propensity
score weights included gender, hypertension, smoking,
family history, hyperlipidemia, prior CABG, prior PCI,
prior stroke or transient ischemic attack, estimated
glomerular filtration rate.
In order to address the role of the implantation tech-
nique used, the following procedural predictors were in-
vestigated separately and as a whole:
1. Predilatation with a balloon of the same nominal
size as the BRS.
2. Vessel size (RVD) comprised between 2.5–3.5 mm
3. BRS sizing: implantation of a BRS of the same size
as the reference vessel diameter (nominal diameter
to reference vessel diameter ratio comprised
between 0.9 and 1.1).
4. Postdilatation at 14-16ATM with noncompliant
balloons of the same size or 0.5 mm larger than
the BRS.
Previous studies have shown that this technique is
associated with a lower incidence of both ScT and ScR
[10, 19].
The significance level was set at p < 0.05. MedCalc
Version 9.2.1.0 (Mariakerke, Belgium) and R Statistical
Software (Foundation for Statistical Computing, Vienna,
Austria) were used for the analysis.
Results
Patients and baseline characteristics
Clinical and procedural characteristics are shown in
Table 1. Of a total of 657 patients, 138 (21%) patients
were diabetics and 519 (79%) were non-diabetics. Pa-
tients in the diabetic group were older (p = 0.016), had a
higher prevalence of hypertension (85% vs. 70%, p = 0.
0005), hyperlipidemia (55% vs. 37%, p = 0.0002) and
prior stroke or TIA (8% vs. 3%, p = 0.0198). Furthermore,
the estimated glomerular filtration rate was lower in the
diabetic group (76 ± 25 ml/min vs. 84 ± 22, p < 0.001).
QCA and angiographic outcome
Although the initial stenosis tended to be less severe in
the diabetic group (diabetic 74.8 ± 13.6% vs control 79.6
± 18.5%, p = 0.036), the residual stenosis after BRS im-
plantation in the diabetic group exceed that in the con-
trol group (16.7 ± 13.3% vs. 13.8 ± 9.9%, p = 0.006).
Correspondingly, the lumen gain was smaller in the dia-
betic group (1.92 ± 0.9 vs. 2.17 ± 0.7 mm, p = 0.001). As a
parameter of BRS expansion and marker of prognosis
[16], the quotient of MLD to the nominal BRS diameter
was not different between groups.
Follow-up
Data are presented in Table 2. The median[IQR] follow-
up was 1044 [763–1198] days in diabetics and 1084
[762–1207] days in non-diabetics (P = 0.328). Although
numerically higher in the diabetic group, the incidence
of events was not significantly different between diabetic
and non-diabetic patients at 30 days and within the first
year after BRS implantation. After one year, the inci-
dence of CV death, ScR and TLR were higher in the dia-
betic group (all P < 0.05). Diabetes did not impact overall
mortality, myocardial infarction and scaffold thrombosis.
In multivariable analysis, diabetes (HR 2.89 [1.55–5.39],
P = 0.0009) was an independent predictor of ScR along
with prior revascularization, type B2/C lesions and the
technique used at implantation. The propensity score
(Table 3) at both the lesion and patient level confirmed
the independent association between DoCE and ScR
Table 1 Patient and procedural characteristics (Continued)
All patients (n = 657) Patients with diabetes (n = 138) Patients without diabetes (n = 519) P-value
Clopidogrel 200/657 (30.4%) 51/138 (37.0%) 149/519 (28.7%) 0.077
Prasugrel 324/657 (49.3%) 67/138 (48.6%) 257/519 (49.5%) 0.915
Ticagrelor 132/657 (20.1%) 19/138 (13.8%) 113/519 (21.8%) 0.076
P < 0.05 as statistically significant are in bold
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rates in diabetics, while the incidence of ScT was not
different between groups. Patient and lesion characteris-
tics after propensity score adjustment are presented in
Additional file 1: Table S1a and b.
Implantation technique
The full implantation technique as described above was
used in 74 patients (54%) of the diabetic and in 237 pa-
tients of the control group (46%) (p = 0.117 between
groups). Outcome data are presented in Figs. 1, 2, and
Tables 4 and 5. In diabetic patients, application of an op-
timal implantation technique was associated with re-
duced incidence of ScR, ScT, TV-MI, TLR and TVR.
Table 5 presents the separated HRs for the impact of the
implantation technique in the two patient groups. Inter-
estingly, a suboptimal implantation technique was asso-
ciated with a marked increase in the risk of ScR (HR 18.
6[4.7–73.3], from 27% to 1%) but not of ScT (3% for
both) in diabetic patients. In contrast, the implantation
technique had a marked impact on ScT (but not ScR) in
non-diabetic patients (Table 5).
Relationship with the vessel diameter
The incidence of ScR was higher in diabetics for all size
of the target vessel (Fig. 3a). The relationship between
incidence of ScR and RVD described a U-shaped curve,
Table 3 Propensity score analysis
Patient level Lesion level
Unadjusted Average treatment effect-adjusted Unadjusted Average treatment effect -adjusted
p HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI
DoCE 0.026 1.74 [1.07–2.83] 0.0026 1.59 [1.18–2.16] 0.045 1.65 [1.01–2.68] 0.003 1.58 [1.17–2.13]
ScT 0.6 0.75 [0.26–2.18] 0.43 0.79 [0.44–1.42] 0.52 0.7 [0.24–2.05] 0.2 0.68 [0.37–1.23]
ScR 0.0067 2.52 [1.29–4.91] 0.00038 2.2 [1.42–3.41] 0.0051 2.37 [1.3–4.35] 0.00077 1.97 [1.33–2.92]
Fig. 1 Incidence of scaffold restenosis in patients with diabetes and patients without diabetes and effect of the implantation technique. The
incidence of ScR was higher in diabetics, but the application of a “full” implantation technique reduced it in diabetics but not in non-diabetics
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demonstrating an increasing risk at both ends of the
RVD spectrum. Due to the lower incidence of ScR, this
trend was less manifest in non-diabetics. When the risk
of ScR was plotted against the relationship between
nominal BRS diameter and RVD, an increased risk was
shown for both undersized BRS (as defined by a BRS at
least 15% smaller than the RVD, ie BRS/RVD ratio < 0.
85) and oversized BRS (BRS/RVD ratio > 1.15) (Fig. 3b).
Finally, in Cox-regression, RVD was a predictor of ScR
in non-diabetics HR:0.38 [0.16–0.93], P = 0.035), but not
in diabetics (HR: 0.46 [0.16–1.31], P = 0.148).
Discussion
Diabetes is a known risk factor and determinant of prog-
nosis after metallic stent implantation. Long-term evi-
dence on the outcome of patients with diabetes treated
with BRS is still scarce. Except for one study [15], data
available report the incidence of events only during the
first year after BRS implantation [12–14], a time that
does not allow conclusions on the risk of ScR. We report
on the impact of diabetes in a cohort of consecutive pa-
tients with a three-years follow-up. Similar to what ob-
served by Muramatsu et al. [14], there was no significant
difference between diabetes and non-diabetes patients in
any of the outcomes during the first year after BRS im-
plantation. After one year, however, diabetes was a pre-
dictor of cardiovascular death, target vessel- and target
lesion-revascularization, and ScR. As a possible mechan-
istic explanation for this observation, the postprocedural
residual stenosis, a procedural parameter that is known
to be associated with worse outcomes [20], was
Fig. 2 Incidence of scaffold thrombosis in patients with diabetes and patients without diabetes and effect of the implantation technique. The
incidence of ScT was not significantly different in diabetics and non-diabetics, although a trend towards a paradoxically lower incidence of late
ScT in diabetics was shown. The implantation technique reduced the incidence of ScT in non-diabetics more than in diabetics
Table 4 Impact of the implantation technique in patients with
diabetes
Diabetes Implantation Technique
No (63) Yes (74) p HR 95% KI
all death 4/63 6%) 7/74 (9%) 0.3415 0.56 0.17–1.84
CV death 3/63 (5%) 6/74 (8%) 0.284 0.48 0.13–1.81
any MI 10/63 (16%) 5/74 (7%) 0.1207 2.28 0.81–6.17
TV- MI 9/63 (14%) 1/74 (1%) 0.006 10.27 1.64–19.80
TLR 19/63 (30%) 2/74 (3%) 0.0001 10.79 22.49–13.97
TVR 25/63 (40%) 7/74 (9%) 0.0001 4.41 1.94–7.86
ScR 17/63 (27%) 1/74 (1%) 0.0001 18.54 2.61–16.80
ScT 2/63 (3%) 2/74 (3%) 0.9722 1.03 0.14–7.45
DOCE 22/63 (35%) 8/74 (11%) 0.0021 3.29 1.51–6.41
P < 0.05 as statistically significant are in bold
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significantly larger in the diabetes group. As previously
published [21], the incidence of ScR appeared to be in-
versely proportional to the size of the target vessel, but
the reference vessel diameter was a stronger predictor of
ScR in non-diabetics as compared to diabetic patients.
In the recent 1-year GHOST-EU analysis [13], a signifi-
cant interaction between diabetes and reference vessel
diameter ≤ 2.75 mm was shown, and in patients with lar-
ger vessels the impact of diabetes was mitigated (rate of
1-year device oriented composite event in patients with
reference diameter > 2.75 mm: 5.7% in diabetics vs. 3.
9%). Taken together, these findings may suggest that ves-
sel size influences the timing (higher risk of device fail-
ure in patients with RVD < 2.75 mm during early follow-
up), but not the long-term impact of diabetes (higher in-
cidence of ScR in patients with diabetes independently
of the vessel size). The present findings further expand
these concepts. Taken as a continuous variable RVD was
not a predictor of events. However, in patients with dia-
betes, the risk of ScR was progressively higher for both
smaller and larger RVDs, describing a U-shaped curve
with lowest incidence for RVDs between 2.75 and 3.
5 mm. This evidence demonstrates that sizing is indeed
important [10, 22]. In analogy, the incidence of ScR was
higher in the presence of mismatch between nominal
BRS size and vessel size (RVD). Of note, this finding is
in line with computational fluid dynamics analyses
showing that both stent/scaffold oversizing and under-
sizing cause blood flow disturbances and recirculation
microenvironments both proximal and distal to the
treated segment, resulting in a stimulus for neointima
formation [23].
Importantly, the association between diabetes and
ScR-related outcomes was maintained when differences
in the cardiovascular risk profile were accounted for in a
propensity score analysis. Finally, in diabetic patients in
whom BRS had been implanted following a set of rec-
ommendations including BRS sizing, correct vessel size
selection, accurate pre- and postdilation, the incidence
of ScR was significantly reduced, demonstrating an im-
pact of the technique used at the time of implantation
also on long-term outcomes.
Limitations
The retrospective, observational nature of the study does
not allow inferring mechanistic conclusions. As well,
despite accurate patient phenotypization with accepted
clinical criteria, bias might exist which were not equal-
ized with the propensity score. Although there was no
external monitoring, 100% of the data were monitored
Table 5 Hazard Ratios with respective 95% confidence interval of the effect of the implantation technique in the two groups
Diabetes without vs. Diabetes
with optimal implantation
Diabetes vs No diabetes, both
with optimal implantation
Diabetes vs No Diabetes, both
without optimal implantation
No diabetes without vs. no diabetes
with optimal implantation
ScT 1.083 [0.215–5.458] 6.641 [1.849–23.854] 0.369 [0.101–1.348] 19.503 [8.451–45.010]
ScR 18.596 [4.719–73.284] 0.419 [0.142–1.233] 5.360 [1.800–15.956] 1.452 [0.728–2.895]
P < 0.05 as statistically significant are in bold
Fig. 3 a Incidence of scaffold restenosis as a function of reference vessel diameter (RVD). The incidence of ScR described a U-shaped curve, with
higher risk at both ends of the RVD spectrum. b Both oversizing (as defined by a BRS/RVD ratio > 1.15) and undersizing (BRS/RVD ratio < 0.85)
were associated with increased ScR risk in diabetic patients
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by staff not responsible for data entry. As well, all events
were adjudicated by experienced cardiologists based on
original documents. Importantly, the classification into
groups was based on the presence of diabetes at the time
of treatment, and we cannot exclude that some of the
patients in the control group had a new diagnosis of dia-
betes during follow-up. Levels of glycol-hemoglobin
were not available, and (like in the previous papers [11–
13, 15]) information on the impact of changes in medical
or insulin treatment during follow-up was not collected.
Of note, in the GHOST-EU subanalysis, diabetic pa-
tients treated with and without insulin had quite similar
clinical, angiographic and procedural characteristics
and nonsignificant differences outcomes [13]. The rate
of ScT reported here is slightly higher than that re-
ported by Muramatsu et al. [14], an observation that is
likely associated with the higher risk profile and the in-
clusion of complex lesion in the present cohort, but it
is lower than that described by Kereiakes et al. [12].
The incidence of cardiovascular death, but not that of
diagnosed myocardial infarction, was higher in the dia-
betes group after 365 days. Although no documentation
suggesting myocardial infarction or scaffold-related
events was available in these cases, a very late event
cannot in principle be excluded. Finally, although we
show a difference in the outcomes in association with
appropriate implantation technique, we cannot provide
a direct comparison between BRS and newer generation
drug eluting stents as recently performed in the UN-
DERDOGS study for long lesions [24]. For comparison,
however, our reported incidence of no scaffold resten-
osis and 1.2% scaffold thrombosis at two years in the
group of diabetics with appropriate implantation tech-
nique are in the same range of (if not lower than) those
previously reported in patients treated with everolimus-
eluting metallic stents [25].
Conclusions
We provide long-term outcome data in patients treated
with BRS. In line with previous evidence with metallic
stents, one year after implantation, diabetes was associated
with an increased incidence of ScR and related outcomes, a
phenomenon that was more pronounced in vessels outside
of the 2.75–3.5 mm range and in the presence of a mis-
match between BRS and vessel size. Of note, this negative
impact of diabetes was reset when an optimal implantation
technique was used. Data on the outcome of these lesions
after BRS resorption is completed are awaited.
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